Scandinavian Biopharma continues to expand and strengthen its organization. In April Kyoko Misawa started as Clinical Study Manager at Scandinavian Biopharma’s research subsidiary ETVAX AB. Kyoko has more than 20 years’ experience from the pharmaceutical and life science industry in both Japan and Sweden within the field of diabetes, antibiotic, inflammation and orphan drugs.
– Scandinavian Biopharma is a very dynamic and fast-growing company. I look forward to help the company grow by utilizing my global experience and knowledge and add value in the development of the new vaccine – ETVAX®,” says Kyoko Misawa, who will be the Clinical study Manager at Scandinavian Biopharma.
In Japan Kyoko worked for Novo Nordisk and Sanofi from late clinical phase until obtaining Market authorization. The last 10 years Kyoko has been based in Sweden. Most recently she worked as Clinical Study Manager at Sobi. Before that she was the Project Manager working on global clinical studies including North America, Latin America, Europe and Japan at WorldWide Clinical Trials.
– I’m very pleased to welcome Kyoko to Scandinavian Biopharma. Her extensive experience in the health care industry, from clinical studies all the way to business development and culture awareness, are key to accompany Scandinavian Biopharma on its growth path, says Björn Sjöstrand, CEO Scandinavian Biopharma.
Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests.
Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.